Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
Article Details
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
Authors (22)
Yves Dauvilliers
National Reference Network for Narcolepsy, Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France
Giuseppe Plazzi
Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS Institute of Neurological Sciences
Emmanuel Mignot
Stanford Center for Sleep Sciences and Medicine, Redwood City, CA
Gert Jan Lammers
Sleep–Wake Center, Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands
Rafael del Río Villegas
Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid
Ramin Khatami
Center of Sleep Medicine and Sleep Research, Klinik Barmelweid, Barmelweid, Switzerland
Mitsutaka Taniguchi
Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan
Anson Abraham
Takeda Development Center Americas, Cambridge, MA
Yaming Hang
Takeda Development Center Americas, Cambridge, MA
Harisha Kadali
Takeda Development Center Americas, Cambridge, MA
Marta Lamberton
Takeda Development Center Americas, Cambridge, MA
Sarah Sheikh
Takeda Development Center Americas, Cambridge, MA
Ellie Stukalin
Takeda Development Center Americas, Cambridge, MA
Rachel Neuwirth
Takeda Development Center Americas, Cambridge, MA
Todd J. Swick
Takeda Development Center Americas, Cambridge, MA
Shinichiro Tanaka
Takeda Development Center Americas, Cambridge, MA
Christian von Hehn
Takeda Development Center Americas, Cambridge, MA
Philipp von Rosenstiel
Takeda Development Center Americas, Cambridge, MA
Hao Wang
Division of Quantitative Sciences, Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA
Alice Cai
Takeda Development Center Americas, Cambridge, MA
Melissa Naylor
Takeda Development Center Americas, Cambridge, MA
Tina Olsson
Takeda Development Center Americas, Cambridge, MA